Brief: Satellos Announces Completion Of Enrollment In Basecamp Phase 2 Clinical Trial Of Forazapadin For Duchenne Muscular Dystrophy
30/09/2026 12:09
BRIEF-Satellos Announces Completion Of Enrollment In Basecamp Phase 2 Clinical Trial Of Forazapadin For Duchenne Muscular Dystrophy Sept 30 (Reuters) - Satellos Bioscience Inc. MSCL.TO:
SATELLOS ANNOUNCES COMPLETION OF ENROLLMENT IN BASECAMP PHASE 2 CLINICAL TRIAL OF FORAZAPADIN FOR DUCHENNE MUSCULAR DYSTROPHY
SATELLOS BIOSCIENCE - TO RELEASE BASECAMP PHASE 2 TOPLINE DATA IN Q1 2027
Source text: ID:nGNXbzLT6m
Further company coverage: MSCL.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Satellos Bioscience
See all newsBrief: Satellos Announces Completion Of Enrollment In Basecamp Phase 2 Clinical Trial Of Forazapadin For Duchenne Muscular Dystrophy
Brief: Satellos Bioscience Files For Mixed Shelf Of Up To $300 Million
Canada Research Roundup: BRP, Satellos Bioscience and WSP Global
NASDAQ RESUMED AT 10:09 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:04 AM